These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 17130267)

  • 1. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    Ushiroyama T; Nosaka S; Ueki M
    Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
    Lai WT; Lee KT; Chu CS; Voon WC; Yen HW; Tsai LY; Sheu SH
    Int J Cardiol; 2005 Feb; 98(3):459-64. PubMed ID: 15708180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
    Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
    Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
    Joukhadar C; Klein N; Prinz M; Schrolnberger C; Vukovich T; Wolzt M; Schmetterer L; Dorner GT
    Thromb Haemost; 2001 Jan; 85(1):47-51. PubMed ID: 11204586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
    Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
    Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
    Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
    Tawfik MK; Ghattas MH; Abo-Elmatty DM; Abdel-Aziz NA
    Eur Rev Med Pharmacol Sci; 2010 Jun; 14(6):499-506. PubMed ID: 20712256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
    Tousoulis D; Bosinakou E; Kotsopoulou M; Antoniades C; Katsi V; Stefanadis C
    Int J Cardiol; 2006 Jan; 106(3):333-7. PubMed ID: 16337041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.